Because TNBC frequently demonstrates an important immunogenic profile, a high number of tumor-infiltrating lymphocytes, and a high level of PD-L1 expression (25, 26), it has been possibly considered the most suitable BC subtype for immunotherapy. This evidence concerns the gene CD274 and neoplasm.